Tern portfolio company Device Authority wins Microsoft award

TERN

Tern Plc (LON:TERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things technology businesses, has noted that Device Authority Limited, a company in which Tern currently holds 53.8% of the equity, has announced that it has won the Rising Azure Technology 2023 Microsoft Partner of the Year Award. Device Authority was honored among a global field of Microsoft partners for demonstrating excellence in innovation and implementation of customer solutions based on Microsoft technology.

Device Authority CEO, Darron Antill commented: “We are delighted that Keyscaler-as-a-service (KsaaS), our cloud-first approach to automated end-to-end device security has been recognized with this award. With today’s global supply chains increasingly relying on interconnected devices and the relaying of timely data to artificial intelligence systems, trust in devices has never been more important. Because these devices are often located outside of the secured network environment, they’ve become a target for bad actors, and a single disruption to a production line can cost an organization up to 5% of its annual profits.

“Leveraging Azure’s capabilities, KSaaS provides an automated and scalable solution to our customers’ device security problems, accelerating their digital transformation and providing resilience throughout their connected infrastructure.”

The Microsoft Partner of the Year Awards recognise Microsoft partners that have developed and delivered outstanding Microsoft-based applications, services and devices during the past year. Awards were classified in various categories, with honorees chosen from a set of more than 4,200 submitted nominations from more than 100 countries worldwide. Device Authority was recognised for providing outstanding solutions and services in Global Rising Azure Technology.

The award recognises a technology partner that has demonstrated strong customer focus and impact by building on Microsoft Azure as their primary cloud platform and scaling their solution by selling with Microsoft. The winning partner solution clearly demonstrates the value of repeatable IP and showcases how technology can solve differentiated value, addresses a unique market need, and improves the customer experience.

The Microsoft Partner of the Year Awards are announced annually prior to the company’s global partner conference, Microsoft Inspire, which will take place on July 18-19 this year. Additional details on the 2023 awards are available on the Microsoft Partner blog: https://aka.ms/POTYA2023_announcement. The complete list of categories, winners and finalists can be found at https://partner.microsoft.com/en-US/inspire/awards/winners.

Tern plc is using its experience in pioneering leading-edge tech combined with a deep reach into expanding world markets to unlock the potential of UK companies who may be starting local, but are dreaming global.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

CAR-T therapy brings new approach to multiple myeloma treatment

CAR-T therapy is being used in multiple myeloma and is being studied earlier in the treatment pathway, with research focused on improving durability, safety and access.

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation.

AI control of machines creates a new market for device trust

AI is beginning to control physical machines, increasing demand for technology that can verify device identity before those machines are allowed to act.

Peptide drug development expands beyond GLP-1

GLP-1 success is widening interest in peptide drug development, with the next phase focused on proving clinical value across new therapeutic areas.

Tern Plc announces 90% take-up of Open Offer

Tern Plc has received valid acceptances for 50.9 million Open Offer Shares, representing approximately 90% of the shares available. The fully underwritten offer will raise approximately £509,368 before expenses, with admission of the new shares expected on 24 September 2026.

Talking Medicines moves to capture pharma demand for better patient intelligence

Tighter US pharma advertising rules could increase demand for patient intelligence, supporting the relevance of Talking Medicines’ DrugVoice platform.

Search